Journal of Ayurveda and Integrative Medicine最新文献

Background: Plant formulations with antidiabetic and antioxidant properties have recently gained popularity due to their lower cost and lesser side effects. Guggul gum is one such formulation that is extensively being used to cure various ailments.

Objective: The present study was designed to explore the antioxidant and antidiabetic properties of the aqua-ethanolic Guggul gum extract (GE) from Commiphora wightii using in silico studies and in vitro assays.

Methods: Gas Chromatography Mass Spectroscopy (GCMS) identified compounds were docked to the Human pancreatic α-amylase (HPA, PDB ID: 1HNY) for in silico studies to predict the inhibition. Molecular dynamics simulations (MDS) were performed using GROMACS for 100 ns. The inhibition of the enzyme was further evaluated at in vitro level to show the compounds' hypoglycemic role.

Results: The extract showed a good amount of phenolic (5.14 ± 0.011 mg), flavonoid (0.66 ± 0.023 mg) and terpenoid (1.08 ± 0.018 mg) content along with a promising free radical scavenging activity of 41.96 ± 4.02%. In the in silico studies, 3 out of 6 GCMS-identified bioactive compounds showed permissible values of bioavailability properties suggesting them as a potential candidate for antidiabetic drugs. Similarly, in molecular docking studies, 3 compounds showed more binding energy than the standard drug acarbose indicating better inhibition. MDS studies showed Compound 4 (Diisooctyl phthalate), was the most stable with the lowest root mean square deviation (RMSD) and root mean square fluctuation (RMSF) values, a consistent radius of gyration (Rg), and stable solvent accessible surface area (SASA). This was further confirmed by in vitro analysis where the pancreatic α-amylase inhibitory activity of the extract and the standard drug (acarbose) were comparable at an IC₅₀ value of 4.17 ± 1.26 mg/mL and 3.69 ± 0.89 mg/mL respectively.

Conclusion: The results demonstrated GE as a potential alternative to commercial antidiabetic drugs. Out of the major 6 GCMS-identified compounds, Compound 4 showed the most stable conformation during MDS studies. However, the isolation of the identified compounds could be done in the future for in vivo studies.

Background: The combination of S. salivarius K12 and M. acuminata are being used as synbiotic, but its safety evaulation is required.

Objective: This study aimed to determine the LD50 of synbiotic containing probiotic Streptococcus salivarius K12 and prebiotic Musa acuminata peel extract.

Materials and methods: The determination of LD50 is done according to the Acute Oral Toxicity test No. 425 (AOT425). For limit test, five female Sprague Dawley rats were given a limit dose of 2000 mg/kg of the synbiotic mixture once orally, and observed for 12 days. For subacute toxicity test, twenty female Sprague Dawley rats were randomised into 4 groups (n = 5). Control group received saline, others received synbiotic mixture at doses 175 mg/kg, 550 mg/kg, and 2000 mg/kg, respectively, and observed for 14 days. Animals were euthanised on day-15, blood was collected, and subjected to haematological and biochemical analyses. Kidney and liver were preserved for histopathological examination.

Result: No significant changes on the average body weight of the animals throughout the study. Haematological parameters and biochemical analysis do not depict any changes related to acute toxicity. Histopathology analysis depicted mild changes on kidney and liver.

Conclusion: Based on the data, the LD50 of the synbiotic formulation is higher than 2000 mg/kb, with no sign of acute toxicity observed on all parameters.

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy marked by the clonal proliferation of the mature, yet dysfunctional B lymphocytes in blood and its subsequent infiltration of the marrow, lymphoid tissues and spleen. The resultant immune dysfunction exposes the body to multiple infections and is a cause of major mortality. Here, we discuss the case of a 46-year-old male suffering from CLL who presented with long-standing episodes of low-grade fever, productive cough and throat irritation, lethargy and pedal edema. He was treatment-naïve at the time of presentation. He was treated in lines of Rajayakshma as per Ayurveda, and Kuruthiputru as per Siddha medicine. After three years of treatment with continued follow up till date, comprising of Shamana Chikitsa (Ayurveda and Siddha internal medications), Sodhana (bio purificatory methods)through Mridu Virechana (therapeutic purgation) using Trivrut Avaleha 35g, Guduchi Rasayana (Tinospora cordifolia) and Yashtimadhu Rasayana(Glycyrrhiza glabra), patient reported reduction in frequency of infections, improved performance score with a mean reduction in TLC counts by 100 thousand/cu. mm in 10 months starting intervention. Presently the patient is stable with occasional episodes of dry cough and generalized weakness. Integrated practices involving Ayurveda and Siddha medicines may be beneficial to patients suffering from CLL by reducing the episodes of infections, improving the quality of life while pacifying the deranged hematological parameters to certain extent.

Venous stasis ulcer is a chronic vascular disease and majorly occurred in lower limbs. Recurrence of ulcer in lower extremities are common in venous stasis ulcer. A 65 years old male patient had a symptoms of non-healing ulcer in right leg nearby right ankle joint in more than three months and associated with itching, hyperpigmentation and pain. A patient had a previous history of Deep Vein Thrombosis. Significant healing in wound observed under the siddha medication such as combination of Siddha Sastric chooranam (Parangipattai chooranam, Palagarai parpam, Irunelli Karpam, Sangu parpam) and Vallarai tablet for internal medication and Triphala chooranam as external medication for washing wounds whereas, Maththan thylam is applied for wound dressing. No recurrence of ulcer was observed after a follow-up of 4 months period. This case report depicted the management of chronic ulcer through Siddha medicines.

Long-term disease-free survival (DFS) of 19 years and 8 months is achieved in an Indian male young patient with Acute Myeloid Leukemia (AML) with a grade 2 Superior Vena Cava (SVC) syndrome treated with chemotherapy and adjunct personalized Ayurvedic treatment with medicines having antipyretic (Jwaraghna), reduces inflammation and swelling (Shothaghna) and rejuvenating (Rasayana) properties and effective in anemia (Pandu) and respiratory diseases (Diseases of pranavaha srotasa) In January 2002, this patient was diagnosed with Pulmonary Kochs and Anti Koch's treatment was given for 6 months. However, due to persistent low-grade fever and supra clavicular lymph node enlargement, he was further investigated with X-Ray Chest in July 2002 revealing mediastinal lymphadenopathy with Right Costophrenic angle pleural effusion. (Grade 2 SVC syndrome). Histopathological report of Supraclavicular Lymph node confirmed the hematolymphoid possibility of acute leukemia. He underwent an aggressive course of chemotherapy from August 2002 to October 2003. Initially four Cycles of Oral Chemotherapy (Tab. Mercaptopurine 100 mg with Cap. Etoposide 100 mg) were administered instead of IV Chemo during the period of August 08, 2002 to December 02, 2002 due to financial problem of patient. Thereafter he was treated with two cycles of consolidation with Inj. Cytarabine (high dose) from December 05, 2002 to January 31, 2003 followed by four cycles of maintenance chemotherapy (Inj. Daunomycin 90 mg and Cytarabine high dose 190 mg) from February 06, 2003 to May 07, 2003 and again four cycles of oral chemotherapy from May 26, 2003 to October 07, 2003 (Tab 6 TG (40 mg) 2 tablets and Cap Posid 100 mg OD for 21 days) The patient started Oral Ayurvedic Medicines (OAM) in August 2002 i.e. at the beginning of chemotherapy which consisted of 3 sets of herbo-mineral Ayurvedic medicines to minimize the side effects of chemotherapy, prevent anemia, and bleeding disorders, strengthen the respiratory system as well as boost immunity to prevent disease recurrence. Since his all pathological parameters were normal and his quality of life was improved significantly, Ayurvedic treatment was stopped in Nov 2008 and he was kept under follow-up. He is asymptomatic without any disease recurrence to date. In this case of AML having grade 2 SVC syndrome with unfavorable prognostic factors as male sex, diagnosis at 24 yrs. age, low socioeconomical status and also with limited life expectancy, a long-term DFS of 19 years and 8 months is reported. It has been achieved by an integrative approach of chemotherapy and personalized adjunct Ayurvedic treatment consisting oral herbo-mineral medicines.